LADENBURG, Germany I July 13, 2022 I Heidelberg Pharma AG (FSE: HPHA) and Chiome Bioscience Inc., Tokyo, Japan, (Tokyo: 4583) today announced the signing of an exclusive, target-specific research and option agreement. Heidelberg Pharma Research GmbH signed this collaboration, which will combine one of Chiome’s monoclonal antibodies against one specific target with Heidelberg Pharma’s proprietary ATAC® platform.

Under the terms of the agreement, Chiome will have access to Heidelberg Pharma’s Amanitin toxin-linker platform technology and has an option for an exclusive, target-specific license for global development and commercialization rights to the product candidate resulting from the research collaboration.

Heidelberg Pharma would be eligible to receive an option fee, development- and sales-related milestone payments of up to 105 million Euro as well as tiered royalties in the mid-upper single digit range.

About Heidelberg Pharma

Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies using its proprietary ATAC® technology and to advance the biological mode of action of the toxin as a novel therapeutic principle. The proprietary technology platform is being applied to develop the Company’s own therapeutic ATACs® as well as in third-party collaborations. The lead candidate HDP-101 is a BCMA ATAC in clinical development for multiple myeloma. HDP-102, a CD37 ATAC for Non-Hodgkin lymphoma and HDP-103, a PSMA ATAC for metastatic castration-resistant prostate cancer, are in preclinical testing.

Heidelberg Pharma AG is based in Ladenburg, Germany, and is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA. More information is available at

ATAC® is a registered EU trademark of Heidelberg Pharma Research GmbH.

About Chiome Bioscience

Chiome Bioscience is a clinical stage biotechnology company. Chiome’s focus is on discovery and development of antibody-based therapeutics in the disease areas with unmet medical needs. Chiome has a proprietary antibody generating technology named ADLib® System and several antibody discovery and preclinical programs. Chiome was founded in 2005, is listed in Tokyo stock exchange Growth (code: 4583), and located in Tokyo, Japan.

For more information, please visit

SOURCE: Heidelberg Pharma